Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells $11,633,048.40 in Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Eliyahu Sharon Kalif sold 345,810 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the sale, the executive vice president directly owned 57,478 shares of the company’s stock, valued at $1,933,559.92. The trade was a 85.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Teva Pharmaceutical Industries Trading Up 1.8%

Shares of NYSE TEVA opened at $32.87 on Thursday. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The stock has a market cap of $37.79 billion, a price-to-earnings ratio of 27.39, a P/E/G ratio of 10.80 and a beta of 0.72. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The company’s fifty day moving average is $33.03 and its 200-day moving average is $26.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400 million to fund development of duvakitug (TL1A antibody), lowering capital risk for Teva’s late‑stage IBD program and accelerating a potential new specialty biologic growth engine. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and nudged its price target higher to $41, signaling continued analyst confidence and providing a visible upside reference for investors. Benzinga coverage of Piper Sandler
• Neutral Sentiment: Coverage highlighting generic-drug headwinds also notes Teva’s strategic push into complex generics and biosimilars as a hedge against price pressure—this supports longer-term growth but doesn’t remove near-term margin risk. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Broader industry commentary about AI adoption in pharma could benefit Teva over time through R&D efficiency and manufacturing optimization, but it’s a longer‑horizon factor rather than an immediate catalyst. Pharmaceutical Executive Daily: Pharma Industry’s AI Adoption
• Negative Sentiment: An executive (EVP Eliyahu Sharon Kalif) disclosed a large sale of 345,810 shares (~$11.6M at the trade price), which can be interpreted by some investors as insider profit‑taking and can weigh on sentiment. Teva EVP Sells 345,810 Shares
• Negative Sentiment: High‑profile investor Stanley Druckenmiller trimmed his TEVA position per 13F filings, a notable name‑level reduction that can be read as profit‑taking and may reduce momentum among discretionary institutional buyers. Billionaire Stanley Druckenmiller Dumped Teva
• Negative Sentiment: A dividend-focused piece recommends an alternative high-yield competitor over Teva, which could damp demand from income investors who are comparing yields and stability. Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TEVA. Scotiabank increased their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $25,000. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust increased its position in shares of Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares in the last quarter. Finally, Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $41,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.